What is the lead time for orders?

The average lead time is one month for both peak and off-peak seasons.

Feed Additive 5% Trace Element Premixed Feed Poultry Premix

Name: Feed Additive 5% Trace Element Premixed Feed Poultry Premix
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1986795945

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$428.00-435.00

10 Tons

Sample price:US$1.00/kg.Request sample

Product profile

Customization

Available

Applied animal classification

Poultry

Certification

ISO

Model NO.

Powder

Shape

Powder

Type

Functional Additives

Active Ingredient

Bacillus Subtilis, Clostridium Butyricum

Function

Bacteriostasis Growth Promoter

Transport Package

25kg/Bag

Specification

25kg/bag

Trademark

Moosun

Origin

China

HS Code

2309901000

Production Capacity

500t/Month

Key features

Improves Egg Quality: Makes eggshells hard and lustrous; improves egg white thickness and poultry spirit.

Extends Laying Period: Long-term use extends peak egg-laying period and delays elimination period.

Protects Intestinal Health: Reduces harmful bacteria like E. coli and significantly reduces diarrhea within 3 days.

Reduces Ammonia: Lowers manure nitrogen and phosphorus, reducing ammonia concentration and respiratory issues.

High Customization: ODM and OEM services available with 20 R&D engineers for tailored solutions.

ISO Certified Quality: Manufactured under ISO certification with advanced production and quality control.

Fast Lead Time: Consistent one-month lead time for both peak and off-season orders.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤15h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.